📊 BDX Key Takeaways
Is Becton Dickinson & Co (BDX) a Good Investment?
Becton Dickinson exhibits critical financial distress with a mathematically impossible 144.3% gross margin, indicating severe data quality issues that undermine analysis credibility. More concerningly, the company's interest coverage ratio of 0.9x signals inability to service debt obligations, combined with concerning profitability metrics (1.5% ROE, 0.7% ROA) suggesting poor capital deployment despite $16.9B in long-term debt.
Becton Dickinson shows solid top-line growth and healthy free cash flow generation, which supports a fundamentally stable operating profile. However, weak net income growth, low returns on equity and assets, and thin interest coverage point to constrained profitability quality relative to its balance sheet size. The business appears fundamentally resilient, but current operating efficiency and leverage coverage metrics argue for a neutral stance rather than a high-conviction bullish view.
Why Buy Becton Dickinson & Co Stock? BDX Key Strengths
- Positive revenue growth of 8.2% year-over-year demonstrates market demand
- Respectable operating cash flow of $657M and free cash flow of $549M provide liquidity buffer
- Reasonable debt-to-equity ratio of 0.67x is manageable in absolute terms
- Revenue growth of 8.2% YoY indicates continued underlying demand and business momentum
- Free cash flow of $549M and a 10.5% FCF margin support internal funding capacity
- Debt/equity of 0.67x is manageable for a large established medical device company
BDX Stock Risks: Becton Dickinson & Co Investment Risks
- Interest coverage ratio of 0.9x indicates the company cannot cover interest expenses from operating income, creating refinancing risk
- Extremely low ROE (1.5%) and ROA (0.7%) demonstrate inefficient capital utilization and poor profitability relative to asset base
- Gross margin of 144.3% is mathematically impossible and indicates fundamental data integrity issues requiring investigation
- Stagnant net income growth (0.0% YoY) and diluted EPS decline (-0.7% YoY) signal operational headwinds despite revenue growth
- Quick ratio of 0.58x combined with $16.9B debt load raises short-term liquidity concerns
- Interest coverage of 0.9x suggests limited earnings cushion against financing obligations
- ROE of 1.5% and ROA of 0.7% indicate weak capital efficiency
- Net income was flat and diluted EPS declined, signaling muted profit conversion despite revenue growth
Key Metrics to Watch
- Interest coverage ratio trend - critical to monitor debt servicing capability
- Actual gross margin reconciliation - resolve the 144.3% anomaly
- ROE and ROA improvement - assess whether profitability metrics are sustainably recovering
- Net income growth acceleration - verify whether revenue growth translates to bottom-line expansion
- Interest coverage and operating income recovery
- Free cash flow consistency relative to revenue growth
Becton Dickinson & Co (BDX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Becton Dickinson & Co presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BDX Profit Margin, ROE & Profitability Analysis
BDX vs Healthcare Sector: How Becton Dickinson & Co Compares
How Becton Dickinson & Co compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Becton Dickinson & Co Stock Overvalued? BDX Valuation Analysis 2026
Based on fundamental analysis, Becton Dickinson & Co has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Becton Dickinson & Co Balance Sheet: BDX Debt, Cash & Liquidity
BDX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Becton Dickinson & Co's revenue has shown modest growth of 8% over the 5-year period. The most recent EPS of $4.94 reflects profitable operations.
BDX Revenue Growth, EPS Growth & YoY Performance
BDX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $5.2B | $303.0M | $1.04 |
| Q3 2025 | $5.0B | $487.0M | $1.68 |
| Q2 2025 | $5.0B | $308.0M | $1.07 |
| Q1 2025 | $4.7B | $281.0M | $0.96 |
| Q3 2024 | $4.9B | $407.0M | $1.36 |
| Q2 2024 | $4.8B | $460.0M | $1.53 |
| Q1 2024 | $4.6B | $281.0M | $0.96 |
| Q3 2023 | $4.6B | $360.0M | $1.18 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Becton Dickinson & Co Dividends, Buybacks & Capital Allocation
BDX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Becton Dickinson & Co (CIK: 0000010795)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BDX
What is the AI rating for BDX?
Becton Dickinson & Co (BDX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BDX's key strengths?
Claude: Positive revenue growth of 8.2% year-over-year demonstrates market demand. Respectable operating cash flow of $657M and free cash flow of $549M provide liquidity buffer. ChatGPT: Revenue growth of 8.2% YoY indicates continued underlying demand and business momentum. Free cash flow of $549M and a 10.5% FCF margin support internal funding capacity.
What are the risks of investing in BDX?
Claude: Interest coverage ratio of 0.9x indicates the company cannot cover interest expenses from operating income, creating refinancing risk. Extremely low ROE (1.5%) and ROA (0.7%) demonstrate inefficient capital utilization and poor profitability relative to asset base. ChatGPT: Interest coverage of 0.9x suggests limited earnings cushion against financing obligations. ROE of 1.5% and ROA of 0.7% indicate weak capital efficiency.
What is BDX's revenue and growth?
Becton Dickinson & Co reported revenue of $5.3B.
Does BDX pay dividends?
Becton Dickinson & Co pays dividends, with $299.0M distributed to shareholders in the trailing twelve months.
Where can I find BDX SEC filings?
Official SEC filings for Becton Dickinson & Co (CIK: 0000010795) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BDX's EPS?
Becton Dickinson & Co has a diluted EPS of $1.34.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BDX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Becton Dickinson & Co has a SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BDX stock overvalued or undervalued?
Valuation metrics for BDX: ROE of 1.5% (sector avg: 15%), net margin of 7.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BDX stock in 2026?
Our dual AI analysis gives Becton Dickinson & Co a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BDX's free cash flow?
Becton Dickinson & Co's operating cash flow is $657.0M, with capital expenditures of $108.0M. FCF margin is 10.5%.
How does BDX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 7.3% (avg: 12%), ROE 1.5% (avg: 15%), current ratio 1.05 (avg: 2).